Unternehmensprofil der M1 Kliniken AG
Unternehmensprofil der M1 Kliniken AG

Unique business model

Company profile

M1 Kliniken AG, based in Berlin, is one of the fastest growing and leading private providers of health services in the beauty sector. With its products and services, the group of companies with more than 200 employees offers a customer-oriented spectrum of aesthetic and surgical treatments throughout Germany. Our experienced and highly specialised team uses high-quality products and state-of-the-art medical technology to perform more than 240,000 minimally invasive and surgical procedures every year to the highest quality standards.

Business model

With the guiding principle "highest quality at the best price", M1 started in 2012 and has established itself as the market leader for beauty medicine in Germany. M1 aims to achieve this leading position in the international beauty segment as well by constantly expanding abroad.

To realize this vision, M1 has developed a unique business model, which is based on specialisation and thus providing the highest quality in medicine. Experts agree on this and for us, top medicine through specialisation is the corporate DNA. M1 Kliniken is the first company to focus on selected treatments within aesthetic and plastic medicine. The results are economies of scale and affordable prices.

More than 90 highly specialized doctors perform more treatments in their field of specialty than regular doctors. This routine increases safety for our clients. Our own training and further education at the M1 Akademie also contributes to this. At the same time, centralised purchasing enables us to use the most modern technical infrastructure and the highest quality products and medicines at attractive prices. With this specialisation, M1 makes top medicine accessible to the general public.

> 200 employees

240,000 treatments annually

> 35 specialist centres worldwide

100 specialist centres by 2024

Latest news

| Investor News

  • Group revenue rises to EUR 237 million (EUR 82 million in Q3-2020)
  • Beauty: treatment numbers at high level; record revenue in German practice network in October 2021; no negative impact from rising incidence rate of the Corona pandemic
  • Group EBITDA amounts to EUR 13.3 million (previous year: EUR 8.8 million); EBIT amounts to EUR 9.1 million (previous year: EUR 5.8 million); EBIT margin in the German practice network in the target corridor of 15-20% despite large number of new openings

| Investor News

  • Significant expansion of site capacities in Germany and internationally
  • Sales in the "Beauty" segment well above the previous year's figures. Expected annual sales of over EUR 50 million in the Beauty segment in 2021

| Investor News

  • Group revenue rises to just under EUR 165 million (EUR 37 million in H1-
    2020)
  • Consolidated EBITDA amounts to EUR 9.9 million (previous year: EUR 1.7
    million); EBIT amounts to EUR 7.1 million (previous year: EUR -0.05
    million)
  • Beauty: Significant increase in treatment and sales figures; Coronarelated
    ‘idle capacity’ due to vaccination intervals

| Investor News

After the Corona-related restrictions of the previous year, the Management Board is confident about the development of the company in the current financial year and the future.